Literature DB >> 27846771

An 8-year population description from a national treatment centre on lymphatic malformations.

Jill Josefine Eliasson1, Inanna Weiss1, Hans Erik Høgevold1,2, Nina Oliver1, Rune Andersen3, Kirsti Try3, Kim Alexander Tønseth1,2,4.   

Abstract

INTRODUCTION: Lymphatic malformations are rare developmental non-malignant abnormalities that present as masses consisting of abnormal growth of fluid filled channels or spaces in the skin or deep tissue that result in abnormalities of lymphatic flow. They may cause symptoms like pain, recurrent lymphorrea, abnormal bone growth, and disturbance of bodily functions. They may also be a cosmetic problem. The study aims to describe the population with lymphatic malformations (LM) treated at a national referral centre.
MATERIALS AND METHODS: This is a retrospective review of patients with the diagnosis lymphatic malformation seen at the centre between 2006-2013. The authors performed a systematic review of the hospital records and a reevaluation of the radiological findings. Eighty-five patients with 102 lymphatic malformations were included.
RESULTS: The majority of the patients (67%) were diagnosed before the age of 2 years. Lesions were located mainly to the head and neck (64%) and half (52%) were macrocystic. Treatment was: sclerotherapy (69%), surgery (49%), laser therapy (19%), or a combination of these treatment modalities (33%). The best outcome was found in the patients with macrocystic lesions (p = .029), and 76% of the patients reported a good or very good outcome.
CONCLUSION: Most patients presented before the age of 2 years with complex lesions which required unique, often multimodal treatment plans and in general they experienced good outcome.

Entities:  

Keywords:  Lymphatic malformation; cystic hygroma; liposuction; lymphangioma; macrocystic; microcystic; sclerotherapy; surgery

Mesh:

Year:  2016        PMID: 27846771     DOI: 10.1080/2000656X.2016.1254092

Source DB:  PubMed          Journal:  J Plast Surg Hand Surg        ISSN: 2000-6764


  5 in total

1.  The Addition of Lipid-Based Contrast Medium does not Inactivate the Detergent Sclerosant Sodium Tetradecyl Sulfate in-vitro.

Authors:  Charlotte L Oliver; Judy Brown; Mike Watkins; Ian McCafferty; Richard J Oliver
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-11       Impact factor: 2.740

2.  National Characteristics of Lymphatic Malformations in Children: Inpatient Estimates and Trends in the United States, 2000 to 2009.

Authors:  Jeffrey Cheng; Beiyu Liu; Alfredo E Farjat; Jonathan Routh
Journal:  J Pediatr Hematol Oncol       Date:  2018-04       Impact factor: 1.289

3.  Indications for tracheostomy in children with head and neck lymphatic malformation: analysis of a nationwide survey in Japan.

Authors:  Shigeru Ueno; Akihiro Fujino; Yasuhide Morikawa; Tadashi Iwanaka; Yoshiaki Kinoshita; Michio Ozeki; Shunsuke Nosaka; Kentaro Matsuoka; Noriaki Usui
Journal:  Surg Today       Date:  2019-02-18       Impact factor: 2.549

4.  Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.

Authors:  Sophie Leducq; Agnès Caille; Sébastien Barbarot; Nathalie Bénéton; Didier Bessis; Olivia Boccara; Anne-Claire Bursztejn; Christine Chiaverini; Anne Dompmartin; Catherine Droitcourt; Valérie Gissot; Dominique Goga; Laurent Guibaud; Denis Herbreteau; Anne Le Touze; Christine Léauté-Labrèze; Gérard Lorette; Stéphanie Mallet; Ludovic Martin; Juliette Mazereeuw-Hautier; Alice Phan; Patrice Plantin; Isabelle Quéré; Pierre Vabres; Hélène Bourgoin; Bruno Giraudeau; Annabel Maruani
Journal:  Trials       Date:  2019-12-17       Impact factor: 2.279

5.  Lymphatic malformations in children: treatment outcomes of sclerotherapy in a large cohort.

Authors:  Frédérique C M Bouwman; Silje S Kooijman; Bas H Verhoeven; Leo J Schultze Kool; Carine J M van der Vleuten; Sanne M B I Botden; Ivo de Blaauw
Journal:  Eur J Pediatr       Date:  2020-10-13       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.